Cardiometabolic Disorders News

The GLP-1 receptor agonist semaglutide may not only add another therapeutic option for chronic kidney disease, but it could also lead to changes in the way clinicians treat the condition.

Children with obesity have increased risk for type 2 diabetes if they are diagnosed with metabolic dysfunction-associated steatotic liver disease, according to findings published in Diabetes Care.

CHICAGO — People living in historically redlined neighborhoods with poor access to healthy foods were more likely to have type 2 diabetes, hypertension, coronary heart disease and obesity, researchers reported.

CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.

CHICAGO — An intensive blood pressure strategy resulted in a lower incidence of major cardiovascular events compared with a more standard strategy among patients with type 2 diabetes and elevated systolic blood pressure in the BPROAD trial.

CHICAGO — In adults with HF with preserved ejection fraction and obesity, treatment with tirzepatide cut risk for CV death or worsening HF by 38% compared with placebo, with a parallel improvement in health status and exercise tolerance.

Genetic variants found in hidradenitis suppurativa may be correlated to genetic variants in coronary artery disease and diabetes, according to a study.

CHICAGO — An AI-enabled tool utilizing machine learning, high-speed images and video accurately detected hypertension and type 2 diabetes among Japanese adults compared with continuous BP monitoring and HbA1c testing, researchers reported.

In this video exclusive, Deidra C. Crews, MD, ScM, FASN, president of the American Society of Nephrology discusses connections between kidney disease and obesity.